

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-012025-0001369

Date: 11.4.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? - We are unable to determine whether the patients were diagnosed within this time, only that they have had an admission and that this condition has been coded. - 100 patients admitted

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months? - 16 patients commenced treatment in the last 6 months, we are unable to say if they are the same patients the are included in the above figures.

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - 5

R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) - 9

Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - 0

Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) - 11

R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) - 0

R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) - 0

R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) - 1

(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) - 1

R-GemOX (rituximab, gemcitabine and oxaliplatin) -0

Axicabtagene ciloleucel 0

Tisagenlecleucel - 0

Epcoritamab - 0

Loncastuximab tesirine - 0

Glofitamab - 0

Any other SACT - 1

Stem cell transplant or bone marrow transplant (autologous or allogeneic) - 0

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

Axicabtagene ciloleucel (Yescarta) - 0
Tisagenlecleucel - 0
Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - 1
R-GemOX (rituximab, gemcitabine and oxaliplatin) - 0
Stem cell transplant or bone marrow transplant (autologous or allogeneic) - Not recorded in our e-prescribing system
Any other treatments - 3

Q4. In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)? - 1

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

CAR-T Therapy (E.g. Axicabtagene ciloleucel) - 0
Stem cell transplant or bone marrow transplant (autologous or allogeneic) - 0
Any other treatment - 0

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust